Skip to main content
SpringerLink
Log in

Hybrid Imaging of Melanoma and Other Cutaneous Malignancies

  • Chapter
  • First Online:
Nuclear Medicine Textbook

  • 2455 Accesses

Abstract

Imaging routinely used for melanoma and other cutaneous malignancies includes ultrasound; contrast-enhanced computed tomography (CT) of the chest, abdomen, and pelvis; magnetic resonance (MR) of the brain; and hybrid modality positron emission tomography/computed tomography (PET/CT).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol. 2014;810:120–40.

    PubMed  Google Scholar 

  2. Ekwueme DU, Guy GP, Li C, Rim SH, Parelkar P, Chen SC. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. J Am Acad Dermatol. 2011;65:S133–43.

    PubMed  Google Scholar 

  3. Colantonio S, Bracken MB, Beecker J. The association of indoor tanning and melanoma in adults: systematic review and meta-analysis. J Am Acad Dermatol. 2014;70:847–57.

    PubMed  Google Scholar 

  4. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351:998–1012.

    CAS  PubMed  Google Scholar 

  5. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103:129–42.

    PubMed  PubMed Central  Google Scholar 

  6. Schüle S-C, Eigentler TK, Garbe C, la Fougère C, Nikolaou K, Pfannenberg C. Influence of 18F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. Eur J Nucl Med Mol Imaging. 2016;43:482–8.

    PubMed  Google Scholar 

  7. Balch CM, Gershenwald JE, Song SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final versions of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.

    PubMed  PubMed Central  Google Scholar 

  8. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim K, Hwu WJ, et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Investig. 2008;26:624–33.

    CAS  Google Scholar 

  9. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U, on behalf of the ESMO Guidelines Committee. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(S5):126–35.

    Google Scholar 

  10. Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol. 2009;27:4774–80.

    PubMed  Google Scholar 

  11. Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE III, et al. Melanoma, Version 2.2016. J Natl Compr Canc Netw. 2016;14:450–73.

    PubMed  Google Scholar 

  12. Petersen H, Holdgaard PC, Madsen PH, Knudsen LM, Gad D, Gravergaard AE, et al. FDG PET/CT in cancer: comparison of actual use with literature-based recommendations. Eur J Nucl Med Mol Imaging. 2016;43:695–706.

    PubMed  Google Scholar 

  13. Gao G, Gong B, Shen W. Meta-analysis of the additional value of integrated 18FDG PET-CT for tumor distant metastasis staging: comparison with 18FDG PET alone and CT alone. Surg Oncol. 2013;22:195–200.

    PubMed  Google Scholar 

  14. Bourgeois AC, Chang TT, Fish LM, Bradley YC. Positron emission tomography/computed tomography in melanoma. Radiol Clin North Am. 2013;51:865–79.

    PubMed  Google Scholar 

  15. Krug B, Crott R, Lonneux M, Baurain JF, Pirson AS, Vander Borght T. Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology. 2008;249:836–44.

    PubMed  Google Scholar 

  16. Bastiaannet E, Uyl-de Groot CA, Brouwers AH, van der Jagt EJ, Hoekstra OS, Oyen W, et al. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma. Ann Surg. 2012;255:771–6.

    PubMed  Google Scholar 

  17. Wagner T, Meyer N, Zerdoud S, Julian A, Chevreau C, Payoux P, Courbon F. Fluoro-deoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node. Br J Dermatol. 2011;164:1235–40.

    CAS  PubMed  Google Scholar 

  18. Wagner JD, Schauwecker D, Davidson D, Logan T, Coleman JJ III, Hutchins G, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer. 2005;104:570–9.

    PubMed  Google Scholar 

  19. Bikhchandani J, Wood J, Richards AT, Smith RB. No benefit in staging FDG-PET in cN0 head and neck cutaneous melanoma. Head Neck. 2014;36:1313–6.

    PubMed  Google Scholar 

  20. Decision Memo for Positron Emission Tomography (FDG) for Solid Tumors (CAG-00181R4). June 2013. www.cms.gov

  21. Jimenez-Requena F, Delgado-Bolton RC, Fernandez-Perez C, Gambhir SS, Schwimmer J, Perez-Vazquez JM, et al. Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma. Eur J Nucl Med Mol Imaging. 2010;37:284–300.

    PubMed  Google Scholar 

  22. Frary EC, Gad D, Bastholt L, Hess S. The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy positive melanoma patients. EJNMMI Res. 2016;6:73. https://doi.org/10.1186/s13550-016-0228-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Rodriguez Rivera AM, Alabbas H, Ramjaun A, Meguerditchian AN. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. Surg Oncol. 2014;23:11–6.

    PubMed  Google Scholar 

  24. Danielsen M, Kjaer A, Wu M, Martineau L, Nosrati M, Leong S, et al. Prediction of positron emission tomography/computed tomography (PET/CT) positivity in patients with high-risk primary melanoma. Am J Nucl Med Mol Imaging. 2016;6:277–85.

    PubMed  PubMed Central  Google Scholar 

  25. Wasif N, Etzioni D, Haddad D, Gray RJ, Bagaria SP, Pockaj BA. Staging studies for cutaneous melanoma in the United States: a population-based analysis. Ann Surg Oncol. 2015;22:1366–70.

    PubMed  Google Scholar 

  26. Koskivuo I, Kemppainen J, Giordano S, Seppänen M, Veräjänkorva E, Vihinen P, Minn H. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma. Acta Oncol. 2016;55:1355–9.

    CAS  PubMed  Google Scholar 

  27. Baker JJ, Meyers MO, Frank J, Amos KD, Stitzenberg KB, Ollila DW. Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma. Am J Surg. 2014;207:549–54.

    PubMed  Google Scholar 

  28. Horn J, Lock-Andersen J, Sjostrand H, Loft A. Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy. Eur J Nucl Med Mol Imaging. 2006;33:887–92.

    PubMed  Google Scholar 

  29. Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol. 2011;65:1032–47.

    PubMed  Google Scholar 

  30. Taghipour M, Marcus C, Sheikhbahaei S, Mena E, Prasad S, Jha AK, et al. Clinical indications and impact on management: fourth and subsequent posttherapy follow-up 18F-FDG PET/CT scans in oncology patients. J Nucl Med. 2017;58:737–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Schröer-Günther MA, Wolff RF, Westwood ME, Scheibler FJ, Schürmann C, Baumert BG, et al. F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review. Syst Rev. 2012;1:62. https://doi.org/10.1186/2046-4053-1-62.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Mohr P, Eggermont AM, Hauschild A, Buzaid A. Staging of cutaneous melanoma. Ann Oncol. 2009;20(Suppl 6):vi14–21.

    PubMed  PubMed Central  Google Scholar 

  33. Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Roses DF, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19:2547–55.

    PubMed  PubMed Central  Google Scholar 

  34. Singnurkar A, Wang J, Joshua AM, Langer DL, Metser U. 18F-FDG-PET/CT in the staging and management of melanoma: a prospective multicenter Ontario PET registry study. Clin Nucl Med. 2016;41:189–93.

    PubMed  Google Scholar 

  35. Forschner A, Olthof S-C, Gückel B, Martus P, Vach W, la Fougère C, et al. Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. Eur J Nucl Med Mol Imaging. 2017;44:1312–8.

    PubMed  Google Scholar 

  36. Krug B, Crott R, Roch I, Lonneux M, Beguin C, Baurain JF, et al. Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma. Acta Oncol. 2010;49:192–200.

    PubMed  Google Scholar 

  37. Dalrymple-Hay MJ, Rome PD, Kennedy C, Fulham M, McCaughan BC. Pulmonary metastatic melanoma – the survival benefit associated with positron emission tomography scanning. Eur J Cardiothorac Surg. 2002;21:611–4.

    CAS  PubMed  Google Scholar 

  38. Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies. Eur J Cancer. 2016;53:125–34.

    PubMed  Google Scholar 

  39. Wong AN, McArthur GA, Hofman MS, Hicks RJ. The advantages and challenges of using FDG PET/CT for response assessment in melanoma in the era of targeted agents and immunotherapy. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):67–77.

    PubMed  Google Scholar 

  40. Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 2014;4:423–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Tavaré R, Escuin-Ordinas H, Mok S, McCracken MN, Zettlitz KA, Salazar FB, et al. An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy. Cancer Res. 2016;76:73–82.

    Google Scholar 

  42. Guldbrandsen KF, Hendel HW, Langer SW, Fischer BM. Nuclear molecular imaging strategies in immune checkpoint inhibitor therapy. Diagnostics. 2017;7 https://doi.org/10.3390/diagnostics7020023.

  43. Wong VK, Lubner MG, Menias CO, Mellnick VM, Kennedy TA, Bhalla S, Pickhardt PJ. Clinical and imaging features of noncutaneous melanoma. AJR Am J Roentgenol. 2017;208:942–59.

    PubMed  Google Scholar 

  44. Murphy G, Hussey D, Metser U. Noncutaneous melanoma: is there a role for 18F-FDG PET-CT? Br J Radiol. 2014;87:20140324.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Duncan JR, Carr D, Kaffenberger BH. The utility of positron emission tomography with and without computed tomography in patients with nonmelanoma skin cancer. J Am Acad Dermatol. 2016;75:186–96.

    PubMed  Google Scholar 

  46. Belkin DA, Wysong A. Radiographic imaging for skin cancer. Semin Cutan Med Surg. 2016;35:42–8.

    PubMed  Google Scholar 

  47. MacFarlane D, Shah K, Wysong A, Wortsman X, Humphreys TR. The role of imaging in the management of patients with nonmelanoma skin cancer: diagnostic modalities and applications. J Am Acad Dermatol. 2017;76:579–88.

    PubMed  Google Scholar 

  48. Humphreys TR, Shah K, Wysong A, Lexa F, MacFarlane D. The role of imaging in the management of patients with nonmelanoma skin cancer: When is imaging necessary? J Am Acad Dermatol. 2017;76:591–607.

    PubMed  Google Scholar 

  49. Hawryluk EB, O’Regan KN, Sheehy N, Guo Y, Dorosario A, Sakellis CG, et al. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women’s Cancer Center. J Am Acad Dermatol. 2013;68:592–9.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Department, Sant Pau Hospital, Autonomous University of Barcelona, Barcelona, Spain

    Montserrat Estorch

Authors
  1. Montserrat Estorch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Montserrat Estorch .

Editor information

Editors and Affiliations

  1. Regional Center of Nuclear Medicine, Department of Translational Research and Advanced Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy

    Duccio Volterrani

  2. Regional Center of Nuclear Medicine, Department of Translational Research and Advanced Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy

    Paola Anna Erba

  3. Hosp. Sant Pau, Nuclear Medicine Department, Autonomous University of Barcelona, Barcelona, Spain

    Ignasi Carrió

  4. Molecular Imaging and Therapy Department, Cornell University Weill, New York, NY, USA

    H. William Strauss

  5. Regional Center of Nuclear Medicine, Department of Translational Research and Advanced Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy

    Giuliano Mariani

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Estorch, M. (2019). Hybrid Imaging of Melanoma and Other Cutaneous Malignancies. In: Volterrani, D., Erba, P.A., Carrió, I., Strauss, H.W., Mariani, G. (eds) Nuclear Medicine Textbook. Springer, Cham. https://doi.org/10.1007/978-3-319-95564-3_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-95564-3_25

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-95563-6

  • Online ISBN: 978-3-319-95564-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation